Evidence map›Paper›PMID 40253348›Full record

ArticleNature communications2025

Nickase fidelity drives EvolvR-mediated diversification in mammalian cells.

Juan E Hurtado, Adam J Schieferecke, Shakked O Halperin, John Guan, Dylan Aidlen, David V Schaffer, John E Dueber

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Anti-CRISPR-mediated continuous directed evolution of CRISPR-Cas9 in human cells.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Juan E HurtadoDepartment of Bioengineering, University of California, Berkeley, Berkeley, CA, USA.
Adam J SchiefereckeDepartment of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, USA.ORCID http://orcid.org/0000-0003-4526-4694
Shakked O HalperinDepartment of Bioengineering, University of California, Berkeley, Berkeley, CA, USA.ORCID http://orcid.org/0000-0002-4221-3595
John GuanDepartment of Bioengineering, University of California, Berkeley, Berkeley, CA, USA.
Dylan AidlenDepartment of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, USA.
David V SchafferDepartment of Bioengineering, University of California, Berkeley, Berkeley, CA, USA. schaffer@berkeley.edu.ORCID http://orcid.org/0000-0002-9625-0121
John E DueberDepartment of Bioengineering, University of California, Berkeley, Berkeley, CA, USA. jdueber@berkeley.edu.ORCID http://orcid.org/0000-0001-8404-7153

Funding

Biology and Biotechnology of Cell and Gene TherapyT32GM139780 · NIGMS · UNIVERSITY OF CALIFORNIA BERKELEY · PI Amy Elizabeth Herr, Dirk Hockemeyer · 2021 to 2026
$2.4M
NIGMS NIH HHS T32 GM139780
6 · The paper itself

Abstract

In vivo genetic diversifiers have previously enabled efficient searches of genetic variant fitness landscapes for continuous directed evolution. However, existing genomic diversification modalities for mammalian genomic loci exclusively rely on deaminases to generate transition mutations within target loci, forfeiting access to most missense mutations. Here, we engineer CRISPR-guided error-prone DNA polymerases (EvolvR) to diversify all four nucleotides within genomic loci in mammalian cells. We demonstrate that EvolvR generates both transition and transversion mutations throughout a mutation window of at least 40 bp and implement EvolvR to evolve previously unreported drug-resistant MAP2K1 variants via substitutions not achievable with deaminases. Moreover, we discover that the nickase's mismatch tolerance limits EvolvR's mutation window and substitution biases in a gRNA-specific fashion. To compensate for gRNA-to-gRNA variability in mutagenesis, we maximize the number of gRNA target sequences by incorporating a PAM-flexible nickase into EvolvR. Finally, we find a strong correlation between predicted free energy changes underlying R-loop formation and EvolvR's performance using a given gRNA. The EvolvR system diversifies all four nucleotides to enable the evolution of mammalian cells, while nuclease and gRNA-specific properties underlying nickase fidelity can be engineered to further enhance EvolvR's mutation rates.

Indexed as

Deoxyribonuclease IDirected Molecular EvolutionDNA-Directed DNA PolymeraseAnimalsCRISPR-Cas SystemsHEK293 CellsHumansMutagenesisMutationRNA, Guide, CRISPR-Cas SystemsDeoxyribonuclease IDNA-Directed DNA PolymeraseRNA, Guide, CRISPR-Cas Systems

Identifiers

PMID40253348
PMCPMC12009436

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.